Sure, you may have missed the chance to snatch up Gentiva Health Services (GTIV) at decade lows, around $3 per share, back in 2011, but the stock is still on sale. The company continues to operate well despite the sequestration overhang (i.e. a possible cut in reimbursement rates). The company has been diversifying its revenue stream via acquisitions and made its best buy of late, snatching up Harden Healthcare, which could be its gateway to community care and away from Medicare focused revenues.
GTIV took its lumps back in 2011, at one point falling 70% in less than a month, when the discussion over reimbursement rate cuts first came to light.
Gentiva is the largest publicly...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: